Sections
| Title | Starting Page | Number of Pages |
|---|
| Table of Contents | 2 | 14 |
| List of Tables | 13 | 2 |
| List of Figures | 15 | 1 |
| Introduction | 16 | 1 |
| Global Markets Direct Report Coverage | 16 | 1 |
| Idiopathic Pulmonary Fibrosis Overview | 17 | 1 |
| Therapeutics Development | 18 | 2 |
| Pipeline Products for Idiopathic Pulmonary Fibrosis Overview | 18 | 1 |
| Pipeline Products for Idiopathic Pulmonary Fibrosis Comparative Analysis | 19 | 1 |
| Idiopathic Pulmonary Fibrosis Therapeutics under Development by Companies | 20 | 4 |
| Idiopathic Pulmonary Fibrosis Therapeutics under Investigation by Universities/Institutes | 24 | 1 |
| Idiopathic Pulmonary Fibrosis Pipeline Products Glance | 25 | 3 |
| Late Stage Products | 25 | 1 |
| Clinical Stage Products | 26 | 1 |
| Early Stage Products | 27 | 1 |
| Idiopathic Pulmonary Fibrosis Products under Development by Companies | 28 | 5 |
| Idiopathic Pulmonary Fibrosis Products under Investigation by Universities/Institutes | 33 | 1 |
| Idiopathic Pulmonary Fibrosis Companies Involved in Therapeutics Development | 34 | 52 |
| AdAlta Pty Ltd. | 34 | 1 |
| Aeolus Pharmaceuticals, Inc. | 35 | 1 |
| Afferent Pharmaceuticals, Inc. | 36 | 1 |
| Apellis Pharmaceuticals Inc | 37 | 1 |
| ARMO Biosciences, Inc. | 38 | 1 |
| Asahi Kasei Pharma Corp. | 39 | 1 |
| Biogen Inc | 40 | 1 |
| Bioneer Corporation | 41 | 1 |
| BiOrion Technologies B.V. | 42 | 1 |
| Bristol-Myers Squibb Company | 43 | 1 |
| Celgene Corporation | 44 | 1 |
| Chrysalis Pharma SAS | 45 | 1 |
| Compugen Ltd. | 46 | 1 |
| Cynata Therapeutics Limited | 47 | 1 |
| F. Hoffmann-La Roche Ltd. | 48 | 1 |
| FibroGen, Inc. | 49 | 1 |
| FibroStatin SL | 50 | 1 |
| Galapagos NV | 51 | 1 |
| GenKyoTex S.A. | 52 | 1 |
| GlaxoSmithKline Plc | 53 | 1 |
| Global Blood Therapeutics, Inc. | 54 | 1 |
| GNI Group Ltd. | 55 | 1 |
| HEC Pharm Co., Ltd. | 56 | 1 |
| Histocell S.L. | 57 | 1 |
| iBio, Inc. | 58 | 1 |
| Immunomet Therapeutics, Inc. | 59 | 1 |
| Inventiva | 60 | 1 |
| Isarna Therapeutics GmbH | 61 | 1 |
| Kadmon Corporation, LLC | 62 | 1 |
| Kasiak Research Private Limited | 63 | 1 |
| Kolltan Pharmaceuticals, Inc. | 64 | 1 |
| Kyorin Pharmaceutical Co., Ltd. | 65 | 1 |
| Lung Therapeutics Inc | 66 | 1 |
| Moerae Matrix, Inc. | 67 | 1 |
| MorphoSys AG | 68 | 1 |
| Novartis AG | 69 | 1 |
| Nuevolution AB | 70 | 1 |
| Pharmaxis Limited | 71 | 1 |
| Promedior, Inc. | 72 | 1 |
| ProMetic Life Sciences Inc. | 73 | 1 |
| Pulmatrix, Inc. | 74 | 1 |
| Respira Therapeutics Inc | 75 | 1 |
| Ribomic Inc. | 76 | 1 |
| Saje Pharma, LLC | 77 | 1 |
| Samumed LLC | 78 | 1 |
| Sanofi | 79 | 1 |
| Sorrento Therapeutics, Inc. | 80 | 1 |
| SPR Biosciences LLC | 81 | 1 |
| Teva Pharmaceutical Industries Ltd. | 82 | 1 |
| Therabron Therapeutics, Inc. | 83 | 1 |
| Vicore Pharma AB | 84 | 1 |
| Yuhan Corporation | 85 | 1 |
| Idiopathic Pulmonary Fibrosis Therapeutics Assessment | 86 | 13 |
| Assessment by Monotherapy Products | 86 | 1 |
| Assessment by Target | 87 | 4 |
| Assessment by Mechanism of Action | 91 | 4 |
| Assessment by Route of Administration | 95 | 2 |
| Assessment by Molecule Type | 97 | 2 |
| Drug Profiles | 99 | 148 |
| AB-22 Drug Profile | 99 | 1 |
| acALY-18 Drug Profile | 100 | 1 |
| AD-114 Drug Profile | 101 | 1 |
| AEOL-10150 Drug Profile | 102 | 9 |
| AF-219 Drug Profile | 111 | 4 |
| AM-0010 Drug Profile | 115 | 3 |
| Antisense RNAi Oligonucleotide for COPD and IPF Drug Profile | 118 | 1 |
| APL-1 Drug Profile | 119 | 1 |
| BG-00011 Drug Profile | 120 | 1 |
| BLR-500 Drug Profile | 121 | 1 |
| BMS-986020 Drug Profile | 122 | 1 |
| BOT-191 Drug Profile | 123 | 1 |
| C-21 Drug Profile | 124 | 2 |
| CC-90001 Drug Profile | 126 | 1 |
| CG-1011 Drug Profile | 127 | 1 |
| CGEN-25009 Drug Profile | 128 | 1 |
| CM-101 Drug Profile | 129 | 1 |
| CT-365 Drug Profile | 130 | 1 |
| CWHM-12 Drug Profile | 131 | 1 |
| D-9030 Drug Profile | 132 | 1 |
| Drugs for Idiopathic Pulmonary Fibrosis Drug Profile | 133 | 1 |
| FSMAB-26 Drug Profile | 134 | 1 |
| FSSME-12 Drug Profile | 135 | 1 |
| GBT-1118 Drug Profile | 136 | 1 |
| GBT-440 Drug Profile | 137 | 4 |
| GKT-831 Drug Profile | 141 | 3 |
| GLPG-1690 Drug Profile | 144 | 2 |
| GLPG-2938 Drug Profile | 146 | 1 |
| Grx1-iSPERSE Drug Profile | 147 | 1 |
| GSK-3008348 Drug Profile | 148 | 1 |
| HEC-585 Drug Profile | 149 | 1 |
| HR-017 Drug Profile | 150 | 1 |
| IBIOCFB-03 Drug Profile | 151 | 2 |
| ICG-001 Drug Profile | 153 | 1 |
| IM-156 Drug Profile | 154 | 1 |
| ISTH-0047 Drug Profile | 155 | 1 |
| IVA-337 Drug Profile | 156 | 1 |
| KAR-5585 Drug Profile | 157 | 1 |
| KBP-7018 Drug Profile | 158 | 1 |
| KD-025 Drug Profile | 159 | 4 |
| KTN-0158 Drug Profile | 163 | 2 |
| lebrikizumab Drug Profile | 165 | 3 |
| LTI-03 Drug Profile | 168 | 1 |
| MMI-0100 Drug Profile | 169 | 2 |
| Monoclonal Antibodies to Inhibit WISP1 for Idiopathic Pulmonary Fibrosis Drug Profile | 171 | 1 |
| MOR-107 Drug Profile | 172 | 1 |
| NAS-911 Drug Profile | 173 | 2 |
| Neumomir Drug Profile | 175 | 1 |
| NUE-7770 Drug Profile | 176 | 1 |
| OLX-101 Drug Profile | 177 | 1 |
| OLX-201 Drug Profile | 178 | 1 |
| omipalisib Drug Profile | 179 | 1 |
| P-013 Drug Profile | 180 | 1 |
| pamrevlumab Drug Profile | 181 | 6 |
| PBF-1129 Drug Profile | 187 | 1 |
| PBI-4050 Drug Profile | 188 | 6 |
| PBI-4425 Drug Profile | 194 | 1 |
| pirfenidone Drug Profile | 195 | 1 |
| pirfenidone Drug Profile | 196 | 1 |
| PRM-151 Drug Profile | 197 | 6 |
| PUR-1500 Drug Profile | 203 | 1 |
| PXS-4820 Drug Profile | 204 | 1 |
| RBM-005 Drug Profile | 205 | 1 |
| RBM-006 Drug Profile | 206 | 1 |
| Refacell-IPF Drug Profile | 207 | 1 |
| RP-6503 Drug Profile | 208 | 1 |
| RT-234 Drug Profile | 209 | 1 |
| SAR-156597 Drug Profile | 210 | 1 |
| SD-560 Drug Profile | 211 | 2 |
| SM-04646 Drug Profile | 213 | 1 |
| Small Molecule for Idiopathic Pulmonary Fibrosis Drug Profile | 214 | 1 |
| Small Molecule to Antagonize AlphaVBetaI for Fibrosis Drug Profile | 215 | 1 |
| Small Molecules for COPD and IPF Drug Profile | 216 | 1 |
| Small Molecules for Liver Fibrosis and Idiopathic Pulmonary Fibrosis Drug Profile | 217 | 1 |
| Small Molecules to Agonize Histamine H4 Receptor for Cystic Fibrosis and Idiopathic Pulmonary Fibrosis Drug Profile | 218 | 1 |
| Small Molecules to Antagonize Integrins for Idiopathic Pulmonary Fibrosis Drug Profile | 219 | 1 |
| Small Molecules to Inhibit Autotaxin for Lung Cancer and Idiopathic Pulmonary Fibrosis Drug Profile | 220 | 1 |
| Small Molecules to Inhibit LOXL2 for Idiopathic Pulmonary Fibrosis Drug Profile | 221 | 1 |
| Small Molecules to Inhibit MRTF and SRF for Idiopathic Pulmonary Fibrosis Drug Profile | 222 | 1 |
| Small Molecules to Inhibit PTPN13 for Idiopathic Pulmonary Fibrosis Drug Profile | 223 | 1 |
| SPL-334 Drug Profile | 224 | 1 |
| SPL-334.1 Drug Profile | 225 | 1 |
| SPL-891.1 Drug Profile | 226 | 1 |
| Stem Cell Therapy for Idiopathic Lung Fibrosis Drug Profile | 227 | 1 |
| Stem Cell Therapy for Idiopathic Lung Fibrosis and Asthma Drug Profile | 228 | 1 |
| Stem Cell Therapy for Idiopathic Pulmonary Fibrosis Drug Profile | 229 | 1 |
| Synthetic Peptide to Antagonize CD168 for Respiratory, Dermatology, Oncology and Musculoskeletal Disorders Drug Profile | 230 | 1 |
| TD-139 Drug Profile | 231 | 1 |
| thrombomodulin alfa Drug Profile | 232 | 2 |
| tipelukast Drug Profile | 234 | 5 |
| vismodegib Drug Profile | 239 | 6 |
| YH-siRNA1 Drug Profile | 245 | 1 |
| ZL-2102 Drug Profile | 246 | 1 |
| Idiopathic Pulmonary Fibrosis Dormant Projects | 247 | 4 |
| Idiopathic Pulmonary Fibrosis Discontinued Products | 251 | 1 |
| Idiopathic Pulmonary Fibrosis Product Development Milestones | 252 | 7 |
| Featured News &Press Releases | 252 | 1 |
| Oct 14, 2016: AdAlta update on Orphan Drug Designation application for lead drug targeting idiopathic pulmonary fibrosis | 252 | 1 |
| Sep 19, 2016: Lanthio Pharma Expands Management Team: Axel Mescheder M.D. Appointed Chief Medical Officer (CMO) of MorphoSys s Dutch Lanthipeptide Subsidiary | 252 | 1 |
| Sep 16, 2016: Presentation of preclinical data on its BET BD1 program at Discovery on Target 2016 | 252 | 1 |
| Sep 14, 2016: Global Blood Therapeutics Announces Publication of Preclinical Results Supporting GBT440 Program for Hypoxemic Pulmonary Disorders | 253 | 1 |
| Sep 12, 2016: AdAlta signs agreement with FujiFilm Diosynth Biotechnologies to begin manufacturing its lead fibrosis drug candidate | 253 | 1 |
| Sep 06, 2016: Orphan Drug Designation in European Union for GLPG1690 in idiopathic pulmonary fibrosis | 254 | 1 |
| Aug 03, 2016: GNI Subsidiary Receives Approval for Etuary 200mg Capsule | 254 | 1 |
| Aug 01, 2016: Vicore Pharma is granted orphan drug designation for C21 for the treatment of IPF | 255 | 1 |
| Jul 24, 2016: MediciNova Receives Notice of Allowance for New Patent Covering MN-001 and MN-002 for the Treatment of Fibrosis | 255 | 1 |
| Jun 20, 2016: Global Blood Therapeutics Announces Initiation of Phase 2a Study of GBT440 in Idiopathic Pulmonary Fibrosis | 255 | 1 |
| Jun 03, 2016: Kadmon Initiates Phase 2 Clinical Trial Evaluating KD025 in Idiopathic Pulmonary Fibrosis | 256 | 1 |
| May 23, 2016: Aeolus Pharmaceuticals to Present at LD Micro Invitational Conference | 256 | 1 |
| Apr 06, 2016: Galapagos initiates a Phase 2a study with GLPG1690 in idiopathic pulmonary fibrosis patients | 257 | 1 |
| Mar 27, 2016: MediciNova Receives Notice of Allowance for New Patent Covering MN-001 in China | 257 | 1 |
| Mar 22, 2016: Synairgen Announces Positive LOXL2 results | 258 | 1 |
| Appendix | 259 | 2 |
| Methodology | 259 | 1 |
| Coverage | 259 | 1 |
| Secondary Research | 259 | 1 |
| Primary Research | 259 | 1 |
| Expert Panel Validation | 259 | 1 |
| Contact Us | 259 | 1 |
| Disclaimer | 260 | 1 |